A phase I study of imatinib, dacarbazine, and capecitabine in advanced endocrine cancers (2014)
Source: BMC Cancer. Unidade: FM
Subjects: NEOPLASIAS DA TIREOIDE (CLASSIFICAÇÃO), METÁSTASE NEOPLÁSICA, CARCINOMA MEDULAR (QUIMIOTERAPIA)
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
HALPERIN, Daniel M. et al. A phase I study of imatinib, dacarbazine, and capecitabine in advanced endocrine cancers. BMC Cancer, v. 14, n. 561, p. (online), 2014Tradução . . Disponível em: https://doi.org/10.1186/1471-2407-14-561. Acesso em: 01 maio 2026.APA
Halperin, D. M., Phan, A. T., Hoff, A. O., Aaron, M., Yao, J. C., & Hoff, P. M. . (2014). A phase I study of imatinib, dacarbazine, and capecitabine in advanced endocrine cancers. BMC Cancer, 14( 561), (online). doi:10.1186/1471-2407-14-561NLM
Halperin DM, Phan AT, Hoff AO, Aaron M, Yao JC, Hoff PM . A phase I study of imatinib, dacarbazine, and capecitabine in advanced endocrine cancers [Internet]. BMC Cancer. 2014 ; 14( 561): (online).[citado 2026 maio 01 ] Available from: https://doi.org/10.1186/1471-2407-14-561Vancouver
Halperin DM, Phan AT, Hoff AO, Aaron M, Yao JC, Hoff PM . A phase I study of imatinib, dacarbazine, and capecitabine in advanced endocrine cancers [Internet]. BMC Cancer. 2014 ; 14( 561): (online).[citado 2026 maio 01 ] Available from: https://doi.org/10.1186/1471-2407-14-561
